Sep 2013

Home >> Clinical Trials News Archive >> 2013 >> Sep 2013
Q-Trials team is proud to announce that we have obtained MoH Approval for a Gene Therapy Study, within several weeks! This is an unprecedented achievement as far as we know, allowing a speedy initiation of a gene therapy study. We owe a great deal to the MoH Clinical Trials department for working relentlessly with our team towards this goal! 

TAU and Technion Connect With China
.
 The life sciences figure prominently in major new collaborations between two Israeli universities and China. Li Ka Shing, one of the wealthiest people in the world, is giving $130 million to the Technion to build a research center in China, a joint project between the Technion and Shantou University, located in Guangdong Province.
 
Outlook brighter for Israeli VC funds, but don’t expect the go-go years. Israeli high-tech appears to be booming, but megadeals like the $1 billion sale of Waze to Google and the approaching initial public offering by Outbrain conceal one of the industry's biggest problems: the meager capital being raised by Israeli venture capital funds. So Pitango Venture Capital's closing of its sixth fund at $270 million this week brightened the atmosphere.
 
The 2nd Annual International Partnering of the Israeli BioMedTech Industry Life Sciences Israel 2013 will be held on 16-17 October 2013 in Dan Panorama Hotel, Tel Aviv.
 
Commercializing Innovation under the Health Reform. The IATI is happy to host Susan Berson, a senior health law specialist and Managing Member of Mintz Levin’s DC office, for a private round table discussion on Tuesday, October 8, in Herzliya Pituach.
 
BrainTech Israel 2013 -Israel’s first international brain technology conference, to be held in Tel Aviv on October 14-15, 2013, hosted by Israel Brain Technologies (IBT). IBT is a non-profit organization, inspired by the vision of Israeli President Shimon Peres, to promote Israel’s neurotechnology innovation hub.